The ClinicalTrials.gov results database--update and key issues
- PMID: 21366476
- PMCID: PMC3066456
- DOI: 10.1056/NEJMsa1012065
The ClinicalTrials.gov results database--update and key issues
Abstract
Background: The ClinicalTrials.gov trial registry was expanded in 2008 to include a database for reporting summary results. We summarize the structure and contents of the results database, provide an update of relevant policies, and show how the data can be used to gain insight into the state of clinical research.
Methods: We analyzed ClinicalTrials.gov data that were publicly available between September 2009 and September 2010.
Results: As of September 27, 2010, ClinicalTrials.gov received approximately 330 new and 2000 revised registrations each week, along with 30 new and 80 revised results submissions. We characterized the 79,413 registry and 2178 results of trial records available as of September 2010. From a sample cohort of results records, 78 of 150 (52%) had associated publications within 2 years after posting. Of results records available publicly, 20% reported more than two primary outcome measures and 5% reported more than five. Of a sample of 100 registry record outcome measures, 61% lacked specificity in describing the metric used in the planned analysis. In a sample of 700 results records, the mean number of different analysis populations per study group was 2.5 (median, 1; range, 1 to 25). Of these trials, 24% reported results for 90% or less of their participants.
Conclusions: ClinicalTrials.gov provides access to study results not otherwise available to the public. Although the database allows examination of various aspects of ongoing and completed clinical trials, its ultimate usefulness depends on the research community to submit accurate, informative data.
Figures
Comment in
-
The ClinicalTrials.gov results database.N Engl J Med. 2011 Jun 2;364(22):2169-70; author reply 2170. doi: 10.1056/NEJMc1103910. N Engl J Med. 2011. PMID: 21631344 No abstract available.
-
The ClinicalTrials.gov results database.N Engl J Med. 2011 Jun 2;364(22):2169; author reply 2170. doi: 10.1056/NEJMc1103910. N Engl J Med. 2011. PMID: 21631345 No abstract available.
-
The ClinicalTrials.gov results database.N Engl J Med. 2011 Jun 2;364(22):2169; author reply 2170. doi: 10.1056/NEJMc1103910. N Engl J Med. 2011. PMID: 21631346 No abstract available.
-
The ClinicalTrials.gov results database.N Engl J Med. 2011 Jun 2;364(22):2169; author reply 2170. doi: 10.1056/NEJMc1103910. N Engl J Med. 2011. PMID: 21631347 No abstract available.
References
-
- Public Law 110-95. Food and Drug Administration Amendments Act of 2007.
-
- Vedula SS, Bero L, Scherer RW, Dickersin K. Outcome reporting in industry-sponsored trials of gabapentin for off-label use. N Engl J Med. 2009;361:1963–71. - PubMed
-
- Glickman SW, McHutchison JG, Peterson ED, et al. Ethical and scientific implications of the globalization of clinical research. N Engl J Med. 2009;360:816–23. - PubMed
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials